# ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis

> **NCT04203108** · PHASE4 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 266 (estimated)

## Conditions studied

- Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** ATG
- **DRUG:** CsA
- **DRUG:** MTX
- **DRUG:** MMF

## Key facts

- **NCT ID:** NCT04203108
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2021-08-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 266 (ESTIMATED)
- **Last updated:** 2019-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04203108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04203108, "ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04203108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*